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Abstract
[11C](R)PK11195-PET measures upregulation of translocator protein (TSPO), which is associated
with microglial activation, [11C]PIB-PET is a marker of amyloid, while [18F]FDG-PET measures
cerebral glucose metabolism (rCMRGlc). We hypothesize that microglial activation is an early
event in the Parkinson’s disease spectrum, and is independent of the amyloid pathology. The aim
of this study is to evaluate in vivo the relationship between microglial activation, amyloid
deposition and glucose metabolism in PDD and PD subjects without dementia. Here we evaluated
eleven PDD subjects, eight PD subjects without dementia and 24 control subjects. Subjects
underwent T1 and T2 MRI, [11C](R)PK11195, [18F]FDG and [11C]PIB PET scans. Parametric
maps of [11C](R)PK11195 binding potential, rCMRGlc, and [11C]PIB uptake were interrogated
using Region of Interest and SPM (statistical parametric mapping) analysis. The PDD patients
showed a significant increase of microglial activation in anterior and posterior cingulate, striatum,
frontal, temporal, parietal and occipital cortical regions compared to the controls. The PD subjects
also showed a statistically significant increase in microglial activation in temporal, parietal and
occipital regions. [11C]PIB uptake was marginally increased in PDD and PD. There was a
significant reduction in glucose metabolism in PDD and PD. We have also demonstrated pixel-by-
pxel correlation between mini-mental state examination (MMSE) score and microglial activation,
and MMSE score and rCMRGlc. In conclusion, we have demonstrated that cortical microglial
activation and reduced glucose metabolism can be detected early on in this disease spectrum.
Significant microglial activation may be a factor in driving the disease process in PDD. Given this,
agents that affect microglial activation could have an influence on disease progression.
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Introduction
Around 80% of Parkinson’s disease (PD) subjects develop dementia if they survive for 20
years with the condition and on average the prevalence is 40% (Cummings, 1988; Hughes et
al, 2000). Parkinson’s disease dementia (PDD) is characterised by impairment of short term
recall, attention, visuospatial and executive functions such as decision making (Emre et al,
2007). Cortical Lewy bodies, Alzheimer pathology, degeneration of subcortical nuclei
including the medial substantia nigra, the cholinergic nucleus basalis of Meynert, the
noradrenergic locus ceruleus and other brain stem nuclei or combination of these factors
contribute to dementia in PDD.
Microglia constitute 10-15% of non-neuronal cells in the brain and normally are in a resting
stage monitoring the brain milieu. Invading pathogens, trauma, infection, degenerative
disease, and stroke can all trigger activation of microglia with the production and release of
reactive oxygen and nitrogen species, cytokines, and chemokines. This intrinsic
‘inflammation’ in the central nervous system may have both beneficial as well as harmful
effects (McGeer and McGeer, 2004; Wyss-Coray and Mucke, 2002). Chronic low levels of
neuroinflamation may lead to progressive damage of the host tissue and it is proposed that
neuroinflamation is associated with all neurodegenerative disorders including Alzheimer’s
and Parkinson’s diseases.
It has been suggested that the chronic inflammation mediated by microglial cells may
contribute to the death of dopamine producing neurons in the brain (Hirsch et al, 2003). In
post mortem studies, it is demonstrated that Alzheimer’s disease β-amyloid fibrils (Aβ) are
associated with activated microglia. As up to 40% of PDD subjects have significant amount
of amyloid, it may be possible that cell loss could arise from the presence of dual pathology
resulting in reduced cortical glucose metabolism (Berding et al, 2001; Eberling et al, 1994;
Feng et al, 2008; Hosokai et al, 2009; Peppard et al, 1992; Sasaki et al, 1992; Yong et al,
2007). To date no effective treatment is available to prevent the progression of PDD. For an
effective treatment strategy, it is important to understand the relative roles of microglial
activation and amyloid deposition, and influence of these on cerebral glucose metabolism.
Marked upregulation of mitochondrial translocator protein (TSPO) expression – also known
as peripheral benzodiazepine binding sites – is associated with microglial activation. [11C]
(R)PK11195 [1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline
carboxamide] PET is a measure of upregulation of TSPO (Shah et al, 1994). In normal brain
tissue specific binding of [11C](R)PK11195 is low as microglia are in a resting state.
Autoradiography combined with immunocytochemical studies has shown that brain binding
of [11C](R)PK11195 closely follows the distribution of microglia activated by brain injury
in conditions such as multiple sclerosis (Banati et al, 2000). Previous PET studies from our
group have reported that increased [11C](R)PK11195 binding could be detected in both
idiopathic Parkinson’s and Alzheimer disease subjects (Edison et al, 2008a; Gerhard et al,
2006).
[11C]PIB (N-methyl-[11-C]2-(4′-methyl amino phenyl )-6-hydroxy benzothiazole), binds to
fibrillar β amyloid in both neuritic and non-neuritic plaques in the cortex and striatum of AD
patients, but not to amorphous β amyloid deposits; the latter can be found in the cerebellum
(Klunk et al, 2003). Studies have reported two-fold increases in cortical uptake of [11C]PIB
in Alzheimer’s disease compared to healthy controls, and a significant proportion of healthy
subjects have high amyloid (Edison et al, 2007; Klunk, 2011; Nordberg et al, 2010; Pike et
al, 2007). Several studies are underway evaluating the progression of AD under Alzheimer’s
disease neuroimaging consortium (ADNI)(Weiner et al, 2012), Australian Imaging
Biomarkers and Lifestyle Flagship study of Ageing (AIBL)(Rowe et al, 2010)
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To date, there has been no attempt to evaluate the relationship between microglial activation,
amyloid deposition, and glucose metabolism in PD and PDD in vivo. Here we hypothesize
that microglial activation plays a significant role in this disease, and is independent of the
amyloid pathology; and is associated with reduction in glucose metabolism. In order to
establish whether these neuropathological substrates are associated, we have used PET to
quantify in vivo specific binding of [11C](R)PK11195, [11C]PIB, and [18F]FDG in PDD
subjects and in PD subjects without dementia, and compared the results with those obtained
for a group of normal subjects.
Methods
Eleven PDD subjects, 8 PD subjects without dementia, and 24 control subjects were
recruited from Imperial College NHS trust and the nearby London hospitals. Each PDD and
PD subjects had three PET scans with [11C](R)PK11195, [11C]PIB and [18F]FDG. Ten
age-matched healthy control subjects had [11C](R)PK11195 PET scans, while eight had
[18F]FDG PET, and 14 healthy control subjects had [11C]PIB PET scans. Six of the PDD
subjects and PD subjects without dementia were recruited as part of a previously published
study by our group (Edison et al, 2008b). All subjects had detailed neurological assessments
including a history from a close relative, routine blood analysis, and detailed
neuropsychometric tests assessing verbal and visual memory, attention, executive,
visuoconstruction, language and recognition memory. Subjects were assigned a diagnosis of
PDD based on consensus clinical diagnostic criteria (Emre et al, 2007). The inclusion and
exclusion criteria for PDD, PD, and control subjects are same as previously described
(Edison et al, 2008b). Dementia was excluded in control subjects and PD subjects without
dementia by detailed clinical examination and psychometric testing while significant
cerebral atrophy was excluded by T1-weighted MRI scan and structural damage by T2-
weighted MRI scan. Permission to perform this study was obtained from the Ethics
Committee of the Hammersmith Hospitals Trust while permission to administer radiotracers
was obtained from the Administration of Radioactive Substances Advisory Committee
(ARSAC) UK.
MRI scanning
MRIs were obtained using a 1.5 Tesla GE scanner. T1 volumetric MRI (3D T1 volume,
pulse sequence RF-Fast, acquisition times TR 30ms, TE 3ms, flip angle 30 degrees, field of
view (FOV) 25 cm, matrix 156 × 256, voxel dimensions 0.98×0.98×1.6 mm.) were acquired
for co-registration and assessment of atrophy while T2 weighted images were acquired to
rule out any structural abnormality in PDD, PD and control subjects.
PET Scanning
PET with [11C](R)PK11195—Subjects underwent [11C](R)PK11195-PET using high-
resolution, high-sensitivity ECAT EXACT HR++ (CTI/Siemens 966) camera (Spinks et al,
2000) at Imperial College London. A 10 minute transmission scan was performed for
attenuation correction. Thirty seconds after the start of the emission scan, a mean dose of
296 (SD± 18) MBq [11C](R)PK11195 in 5 ml normal saline was injected intravenously over
10 seconds. Emission data were then acquired over 60 minutes in list-mode and rebinned
into 18 time frames post acquisition.
PET with [11C]PIB—All subjects had an intravenous bolus injection of [11C]PIB (mean
injected dose 370 (SD±20) MBq), and were scanned using a Siemens ECAT EXACT HR+
scanner (Brix et al, 1997) as previously described (Edison et al, 2007). Dynamic emission
scans were acquired in three-dimensional mode over 90 minutes. All data processing and
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image reconstruction were performed using standard Siemens software which included
scatter correction.
PET with [18F]FDG—All PD and PDD subjects and healthy controls were scanned using
a Siemens ECAT EXACT HR+ scanner. Subjects were asked to fast for four hours before
the bolus injection of 185 (±8) MBq of [18F]FDG. A 60 minute dynamic emission scan was
acquired using a predefined protocol with time frames 1×15s, 1×5s, 4×10s, 4×30s, 4×60s,
4×120s and 9×300s. All subjects had radial artery cannulation. Continuous online sampling
was performed for 15 minutes and then discrete blood samples were taken at baseline, 5, 10,
15, 20, 30, 40, 50 and 60 minutes. A haematocrit was estimated from the baseline blood
sample and plasma glucose levels were measured on selected samples. Due to the blockage
of arterial cannula, we were unable to estimate rCMRGlc in two PD subjects.
Analysis of PET scan data
Analysis of [11C](R)PK11195-PET data
Cluster analysis: Parametric images of [11C](R)PK11195 binding potential (BP), reflecting
Bmax/Kd, were generated with a simplified tissue reference two brain compartmental model
(SRTM). As PDD and PD patients have widespread distribution of pathological changes, no
single region free of disease can be identified as a reference for non-specific tracer binding.
Cluster analysis was, therefore, used to extract and identify a distributed cluster of voxels
that mirrored a normal population cortical reference input function for each individual PDD
and PD subject. We have introduced a novel computational methodology that enables the
extraction of a reference cluster from [11C](R)PK11195 dynamic PET studies (Turkheimer
et al, 2007). The use of an appropriate reference not only increases the sensitivity of the
quantification procedure to the specific signal from microglia but also minimizes the
sensitivity of the calculated binding potential (BP), obtained by the modelling procedure, to
changes in blood flow. Our unit has validated use of the SRTM with a reference input
function defined by cluster analysis as the most reproducible and sensitive technique for
generating BP maps (Anderson et al, 2007).
Analysis of [11C]PIB PET data
Target region to cerebellum ratios (RATIO): Target region to cerebellar [11C]PIB uptake
ratio images were created by dividing integrated 60-90 minute voxel tracer uptake by that of
cerebellar grey matter as previously described (Edison et al, 2007). Target to cerebellar ratio
at a later time point provides a blood flow independent measure of specific [11C]PIB
retention that is easy to calculate and does not require arterial sampling (Lopresti et al,
2005).
Analysis of [18F]FDG-PET data—Parametric maps of absolute rCMRGlc were
generated with spectral analysis using an arterial input function as previously described
(Cunningham and Jones, 1993; Hu et al, 2000). We used a lumped constant of 0.48. For ROI
analysis of [18F]FDG scans all the individual images were coregistered to their
corresponding MRIs and then normalised to MNI space as described below.
Region of Interest (ROI) analysis—Parametric maps of [11C](R)PK11195 binding
potential maps were coregistered to the individuals’ MRIs and spatially transformed into
MNI space using SPM99, while [11C]PIB uptake RATIO image was created in MNI space.
Object maps were created by segmenting MRIs into grey matter, white matter and CSF. This
binarised grey matter map was convolved with the latest version of a probabilistic brain
atlas(Hammers et al, 2003) to create individualized object maps of volumes of interest as
previously described(Edison et al, 2007).
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We then sampled the [11C](R)PK11195 binding maps and RATIO images using Analyze
AVW 8.1 in the following regions: whole cortex, frontal, temporal, parietal and occipital
association cortices, anterior and posterior cingulate gyrus, striatum and thalamus. A sub-
regional analysis of the temporal lobe was also performed. Levels of microglial activation
and amyloid load in the hippocampus, parahippocampal gyrus, amygdala, middle and
inferior temporal gyrus were also computed.
Statistical Parametric mapping (SPM) analysis—Parametric images were smoothed
with 6mm x 6mm x 6mm kernel filter prior to SPM analysis. Significant increases in
microglial activation, amyloid load and glucose metabolism in patients compared with
control subjects were localised using a voxel threshold of p<0.005 and cluster extent
threshold of 50 voxels. If there was no significant cluster at the above defined threshold,
voxel threshold was dropped to p<0.05 and cluster extent threshold of 50 voxels in order to
detect small changes. Significant differences in levels of microglial activation and glucose
metabolism between PDD and PD were interrogated using a voxel threshold of p<0.05 and
extent threshold of 50 voxels. Statistical maps were corrected for multiple comparisons
using cluster level inference derived from random field theory as implemented in SPM.
Since ROI analysis evaluates larger cortical regions, to evaluate smaller changes in
microglial activation, glucose metabolism, and amyloid load, each single subject was
compared against the corresponding control group for all the three tracers using SPM.
Statistical analysis: Statistical interrogations of ROI data were performed using SPSS for
Windows version 19 (SPSS, Chicago, Illinois, USA). Since from past experience and on
theoretical grounds we expected only increases in [11C]PIB uptake and [11C](R)PK11195
BP in PDD compared with controls we used one tailed Student’s t tests to interrogate the
ROI data. The correlation between microglial activity and cognitive scores was tested pixel-
by-pixel using SPM where pixel-wise BP of [11C](R)PK11195 PET was the dependent
variable and the MMSE scores were the covariate of interest. Similarly, correlation between
glucose metabolism and cognitive scores were tested using SPM where pixel-wise rCMRGlc
was the dependent variable and the MMSE scores were the covariate of interest.
Additionally, we have performed correlation between [11C](R)PK11195 BP and rCMRGlc
for individual subject for each of multiple regions.
Results
[11C](R)PK11195 PET
Supplementary table 1 shows the demographic details of the subjects, while supplementary
table 2 shows the details of neuropsychometric tests. The mean regional [11C](R)PK11195
binding potentials for the PDD, PD, and control subjects are detailed in table 1A. The PDD
patients showed a statistically significant 35 – 65% increase of [11C](R)PK11195 BP in
different cortical and subcortical regions. Individually, six PDD subjects showed significant
increases (more than mean control BP +2SD) in these regions. The PD subjects showed a
statistically significant 25 - 30% increase of microglial activation in the temporal and
occipital regions. The frontal and parietal regions also showed increases in microglial
activity but just below the statistical threshold for significance (frontal cortex, p =0.064, and
parietal cortex, p =0.06). Individually three of the PD subjects showed significant increases
(more than mean control BP+2SD) in microglial activation in the anterior and posterior
cingulate and frontal, temporal, parietal and occipital cortical regions.
Figure 1A shows the SPM analysis comparing [11C](R)PK11195 BP increases in the 11
PDD subjects compared with 10 control subjects. SPM shows significant increases in
microglial activity in frontal, temporal, parietal and occipital cortical regions at a voxel
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threshold of p<0.005 and extent threshold of 50 voxels. Details of the cortical regions with
increased uptake are shown in table 3A. Figure 1B demonstrates significant increases in
[11C](R)PK11195 BP for eight PD subjects compared to ten control subjects in temporal,
parietal and occipital cortical regions at voxel threshold of p<0.005 and an extent threshold
of 50 voxels. Table 3B details the significant clusters detected using SPM. The comparison
between PDD and PD subjects with a threshold of p<0.05 and extent threshold of 50 voxel
revealed a significant relative increase in BP in PDD in the left parietal lobe (MNI
coordinates -30, -34, 54) with a cluster size of 5387 voxels (p<0.0001) (see figure 2A). SPM
analysis of single subjects demonstrated significant increase in microglial activation in 10
PDD subjects while all PD subjects except one demonstrated significant increase in
microglial activation. Figure 4 is an example of increases in microglial activation in a single
PDD and a PD subject using “single subject SPM analysis”.
[11C]PIB-PET
The details of [11C]PIB uptake ratios in PDD subjects and PD subjects in comparison to the
control subjects are given in table 1B. All subjects had an [11C]PIB uptake RATIO of less
than 1.4 in cortical regions except for one PD subject where the [11C]PIB uptake was
increased in posterior cingulate and one PDD subject who showed an uptake ratio of 1.5 in
the occipital cortical region. Interestingly this PDD patient showed a reduction in glucose
metabolism (rCMRGlc=0.16, where mean-2SD was 0.186) in the anterior temporal lobe.
SPM did not detect any significant increase in the [11C]PIB uptake between PD and
controls nor PDD and controls as a group. Single subject SPM analysis demonstrated that
eight PDD subjects and two PD subjects showed significant increase in amyloid. When
amyloid load was present, it was predominantly in the cortical regions including anterior and
posterior cingulate cortices. However, subjects who did not have any amyloid load did have
increased microglial activation and reduced glucose metabolism in the temporoparietal
cortical regions.
[18F]FDG PET
The regional cortical rCMRGlc for eleven PDD and six PD subjects are given in table 2C.
PDD subjects showed significant reductions in glucose metabolism compared to the control
subjects in the posterior cingulate, temporal, parietal and occipital cortical regions.
Interestingly, parieto-occipital hypometabolism was significantly decreased compared to the
temporal region. Individually 9 out of the 11 PDD patients showed a significant reduction in
glucose metabolism in the parieto-occipital or posterior cingulate. Neuropsychometric
scores did not correlate with the cerebral glucose metabolism.
SPM analysis (illustrated in Figure 3B) also showed a significant reduction in glucose
metabolism in PDD subjects compared to the control subjects in frontal, temporal, parietal
and occipital regions at a voxel threshold of p<0.005. There were two large clusters with a
Z-score of 5.97 and cluster size 83154 one on either side with a corrected p<0.0001. SPM
analysis revealed reductions in glucose metabolism in temporal, parietal, occipital and also
in frontal cortical regions for the PD cohort using a cluster threshold of p<0.05. (Due to
technical reasons, we were unable to estimate two PD subjects’ rCMRGlc) Results from the
SPM analysis are illustrated in Figure 3A and significantly reduced clusters are listed in
supplementary table 3. An SPM comparison between PDD and PD subjects with a threshold
of p<0.05 and extent threshold of 50 voxel showed there was a significant relative reduction
of glucose metabolism in frontal, temporal, parietal and occipital cortical regions in PDD
compared to PD subjects (see figure 2B). SPM revealed large clusters of reduced rCMRGlc
(95409 voxels, corrected p<0.0001) covering both hemispheres. Single subject SPM analysis
demonstrated clusters of reduced rCMRglc for all PD and PDD subjects, with PDD subjects
showing even grater reduction in glucose metabolism compared to PD subjects. Figure 4
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demonstrates reduction in glucose metabolism in single PDD and PDD subjects compared to
control subjects.
Correlation between MMSE sores, [11C](R)PK11195 BP, and rCMRGlc
Pixel-by-pixel correlation between microglial activation and MMSE scores demonstrated an
inverse correlation between cortical microglial activation (temporoparietal, occipital and
frontal) and MMSE scores. Similarly, temporoparietal and occipital reduction in rCMRGlc
was correlated with MMSE scores. Figure 5A demonstrates the significant clusters of
microglial activation using regression analysis of [11C]PK11195 BP against MMSE score in
11 PDD subjects at a cluster threshold of p<0.00005 with extent threshold of 200 voxels,
where cortical microglial activation was inversely correlated with MMSE in PDD subjects.
Figure 5B demonstrates the significant clusters using regression analysis of rCMRGlc
against MMSE score in 11 PDD subjects at a cluster threshold of p<0.00005 with extent
threshold of 200 voxels. The details of the coordinates are given in supplementary table 4.
Cortical rCMRGlc was correlated with the MMSE scores. However, we did not demonstrate
significant inverse correlation between microglial activation and rCMRGlc in the cortical
region using ROI analysis. In figure 6 we have overlaid SPM maps of microglial activation
and glucose metabolism on SPM templates, which indicates that there is significant overlap
between microglial activation and glucose metabolism in several cortical regions, however,
there were areas where microglial activation and glucose metabolism were disconnected.
Discussion
In this study, we have demonstrated that cortical microglial activation is increased in both
PDD and PD subjects compared to healthy control subjects, the spatial extent of the
activation being greater in PDD where brainstem was also involved. Maximal microglial
activation was detected in parieto-occipital cortex but frontal, temporal and anterior and
posterior cingulate cortical regions also showed significant increases. Using [11C]PIB as a
PET marker for fibrillar β amyloid, we were able to detect increases in amyloid as a group
both in PDD and PD. Using group mean ROI analysis, rCMRGlc was reduced in posterior
cingulate, temporal, parietal, and occipital cortical regions in the PDD subjects compared to
controls. The majority of the PDD subjects individually showed a reduction in glucose
metabolism in the hippocampus and in the temporo-parietal and occipital regions. We have
also demonstrated temporo-parietal hypometabolism in the non-demented PD patients using
SPM analysis.
This study demonstrated significant cortical microglial activation in both non-demented and
demented PD subjects. This may suggest that neuroinflammation could be an early
phenomenon in this disease spectrum, and may appear even before the onset of dementia
and could persist as the disease advances. Neuroinflammation is the defence mechanism of
living brain for external injury and acts in two ways: either by rescuing damaged cells or by
further destroying them depending on the anti-inflammatory and pro inflammatory
properties of the cytokines released. When microglia are activated, expressing the TSPO,
they become phagocytic and release a variety of cytokines such as TNFα, IL1, IL2, IL6, and
NO. It is suggested that these substances can be involved in cellular injury and neuronal
degeneration or can act as growth factors. It is shown that in degenerative disease like
Alzheimer’s disease, activated microglia and raised cytokine levels are present around the
senile plaques, stimulating amyloid precursor protein production which in turn leads to
excessive production of β-amyloid. The β-amyloid fibrils in turn cause further microglial
activation resulting in a vicious cycle.
Like senile plaques, the aggregated α-synuclein in Lewy bodies attracts activated microglia
potentially leading to neuronal death and driving disease progression (Zhang et al, 2005). As
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a group, there was increased microglial activity in cortical association regions in both PD
and PDD subjects, more extensive in the latter, but individual analyses showed some
variability between subjects. There was some discrepancy between the number of subjects
who demonstrated increased microglial activation between ROI analysis and single subject
SPM analysis. This could partly be due to the relatively large regions included in the ROI
analysis, while SPM analysis picks up the clusters which demonstrates significant microglial
activation. One possible explanation for variability in microglial activation could be due to
the heterogeneity of the subjects and variability in cortical levels of Lewy body pathology
present in different subjects. It may be possible that microglia may become activated with
some toxic insult, and when the toxic insult is over, microglia could return to dormant stage.
Once microglia are activated, release of cytokines and toxic substances may cause neuronal
damage but one could speculate that even if the microglial activation then subsides the
neuronal damage continues as apoptotic cascades are already initiated. A previous study
from our unit reported that PD patients without dementia did not show a significant
difference in cortical microglial activation over a period of time in support of this point of
view. Here, we have now shown that cortical microglial activity is significantly increased
both in non-demented and demented PD subjects. This may suggest that early and persistent
microglial activation may be one of the factors influencing progressive cognitive
dysfunction in this disease spectrum. However, one could also argue that microglial
activation in PD may not be associated with dementia. McGeer et al has demonstrated
presence of microglilal activation and dopaminergic cell loss in the Substantia Nigra of
monkeys after 5.5 to 14 years following brief exposure to MPTP (1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine) (McGeer et al, 2003), suggesting even if the initial insult
is over, microglial activation and neuronal damage could continue. It is also suggested that
microglial activation could be episodic causing progressive neuronal loss, and eventually
reactive microglia could burn out, while the neuronal damage continues. However,
microglial activation in PD can’t be explained by this as these subjects have significantly
less cortical atrophy compared to the PDD subjects (Data not presented in this paper). Our
failure to detect activated microglia in all subjects with PDD could reflect either insufficient
sensitivity of the [11C](R)PK11195 PET approach and/or the presence of other processes
responsible for neuronal damage. The latter could involve activation of astrocytes by the
cortical Lewy body pathology or initiation of autophagy and apoptotic cascades.
Alternatively, microglial activation could switch on and off depending on the nature of the
insult - it is known that after stroke microglial activation eventually subsides. Recent study
in a small number of subjects have demonstrated that microglial activation is also elevated
in subjects with Lewy body dementia (Iannaccone et al, 2012) A previous study from our
group of non-demented Parkinson’s disease subjects reported the presence of raised
microglial activity in subcortical regions including striatum, pallidum, thalamus and pons
along with cortical regions (Gerhard et al, 2006). We have replicated those findings in this
new study with ROI analysis. Minor variations in the statistical significance could be due to
the heterogeneity of the subjects in these two studies.
In this study our PDD patients showed a reduction in cortical glucose metabolism
particularly temporo-parietal and occipital regions. Widespread cortical hypometabolism
with particularly severe involvement of the temporoparietal areas have been reported in
earlier studies in PDD (Klein et al, 2010; Peppard et al, 1990; Vander Borght et al, 1997).
Studies have also noted cortical involvement particularly temporo-parietal areas in non-
demented PD patients but to a lesser degree compared to PDD (Hu et al, 2000). We have
also demonstrated that reductions in glucose metabolism can be detected in non-demented
PD subjects using SPM analysis. Even though the number of subjects studied in this project
are small, this may suggest that cortical neuronal dysfunction as evidenced by reduced
glucose metabolism is present in PD, even with out significant cognitive impairment. The
lack of significant difference in ROI analysis could be due to the involvement of relatively
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smaller areas (clusters) rather than involvement of larger predefined regions. While PD
traditionally has been defined by its characteristic motor hallmarks, non-motor features such
as cognitive impairment and dementia are increasingly recognized as part of PD. Mild
cognitive impairment is common in non-demented PD patients, occurring in about 20-50%.
It is possible that some of the PD subjects in this study could be in the transitional phase
between PD and PDD.
Reduction in cortical hypometabolism has been previously reported in PD subjects
(Borghammer et al, 2010). Some studies have also reported hypermetabolism in subcortical
structures. Borghammer et al have demonstrated these hypermetabolism found in PD could
be due to the global mean normalisation used in the analysis (Borghammer et al, 2009).
They have also demonstrated that depending on the type of analysis used, even the extent of
the hypometabolism could vary. Here we have quantitatively evaluated cerebral glucose
metabolism using spectral analysis, and the data was not normalised to global mean.
In this study reductions in cortical glucose metabolism were associated with increases in
microglial activation across the combined PD and PDD cohorts. Except for the presence of a
small focal increase in anterior cingulate [11C]PIB uptake in one subject, raised amyloid
load did not appear to be associated with PDD using ROI analysis. Individual SPM analysis
at a threshold of p<0.05, demonstrated that eight PDD subjects and four PD subjects have
minimal amount of amyloid, even though these increases were not obvious in the ROI
analysis. In a previous study we have found 20% of PDD subjects had increased cortical
amyloid using ROI analysis. Recently published [11C] PIB studies (Gomperts et al, 2008;
Maetzler et al, 2009; Maetzler et al, 2008) have also reported increased amyloid load in
PDD subjects. It is also reported that in [11C]PIB+ve subjects in PDD and DLB, ApoE4
prevalence was higher, CSF Abeta42 levels were lower and, among demented subjects,
[11C]PIB binding was associated with a lower MMSE score, suggesting LBD subjects with
cortical beta-amyloid show characteristics usually observed in AD (Maetzler et al, 2009).
Motor symptoms were not associated with [11C]PIB binding in this study.
Neuropathological studies have reported that striatal amyloid can be found in PDD,
however, this is usually diffuse rather than fibrillar in nature and does not necessarily bind
thioflavin ligands such as [11C]PIB (Jellinger and Attems, 2006; Liang et al, 2006). This
may explain the lower prevalence of amyloid in PDD reported in PET studies compared
with pathological series.
Our findings suggest that persistent microglial activation along with small amount of
fibrillar amyloid load is associated with the neuronal damage and reduction in glucose
metabolism in PDD. Studies in Lewy body dementia using [11C]PIB PET has demonstrated
abundant amyloid. Even though not supported by the presented data, it is feasible that the
presence of amyloid could accelerate the dementing process in DLB. In this disease
spectrum, apart from amyloid pathology, loss of cholinergic and monoaminergic projections
could also contribute to cognitive difficulties.
In this study for the first time we have also demonstrated a correlation between cortical
microglial activation and MMSE, further suggesting microglial activation may be associated
with neuronal damage in PDD. However, we did not find such a correlation with other
memory test scores. We were also able to demonstrate that there was a correlation between
cerebral hypometabolism and MMSE, which is well established.
Limitations
One of the limitation of this study is the small number of subjects studied in each group.
This study is a triple tracer study, and due to the intensity of the scanning involved, we were
not able to include large number of subjects. However, in this preliminary study we were
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able to demonstrate novel findings which forms the basis of larger studies. While [11C]
(R)PK11195 PET is a measure of microglial activation, it has relatively low in vivo specific
binding. One study evaluating [11C](R)PK11195 PET and [11C]PBR28 PET has
demonstrated that in vivo binding of [11C](R)PK11195 PET is 80 fold lower than second
generation TSPO tracer, [11C]PBR28. It is also suggested that this relatively low in vivo
specific binding of [11C](R)PK11195 PET may have obscured the detection of non-binding
in peripheral organs. To gain insight into this issue, we are now evaluating different types of
dementia with the novel TSPO tracers.
In conclusion, we have demonstrated that cortical microglial activation and reduced glucose
metabolism can be detected in PD and PDD subjects. Microglial activation was inversely
correlated with MMSE, while rCMRGlc was correlated with MMSE. Given this, agents that
suppress or reverse microglial activation could be a potential protective treatment for
neurodegenerative diseases like PDD but, if they were to be effective, would need to be
started ahead of the appearance of dementia.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
[11C](R)PK11195 uptake in PDD and PD subjects compared to controls.
A shows [11C](R)PK11195 uptake in 11 PDD subjects compared with 10 control subjects
showing significant increase in microglial activity in frontal, temporoparietal and occipital
cortical regions at a p<0.005 and extent threshold of 50 voxels. B shows [11C](R)PK11195
uptake in eight PD subjects compared with 10 control subjects showing significant increase
in microglial activity in temporoparietal and occipital cortical regions at a p<0.005 and
extent threshold of 50 voxels.
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Figure 2.
Statistical Parametric Mapping analysis of [11C](R)PK11195 BP and rCMRGlc between
PDD and PD subjects.
A: Statistical Parametric Mapping (SPM) analysis of [11C](R)PK11195 BP between PDD
and PD subjects.
Shows minimally increased microglial activity in PDD compared to PD using [11C]
(R)PK11195 in11PDD subjects compared to eight PD subjects at voxel threshold of p<0.05
and extent threshold of 50 voxels.
B: Statistical Parametric Mapping (SPM) analysis of rCMRGlc between PDD and PD
subjects.
Shows significantly reduced glucose metabolism in PDD compared to PD using [18F]FDG
PET in11PDD subjects compared to six PD subjects at voxel threshold of p<0.05 and extent
threshold of 50 voxels.
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Figure 3.
Statistical Parametric Mapping (SPM) analysis of rCMRGlc in PDD and PD subjects
compared to the controls
A shows reduction in rCMRGlc in 11 PDD subjects compared with eight control subjects
showing significant reduction in frontal, temporoparietal and occipital region at voxel
threshold of p<0.005 and extent threshold of 50 voxels. B shows reduction in rCMRGlc in
eight PD subjects compared with eight control subjects showing significant reduction in
frontal, temporoparietal and occipital region at voxel threshold of p<0.05 and extent
threshold of 50 voxels.
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Figure 4.
Single subject SPM analysis of microglial activation and glucose metabolism in PDD and
PD subjects against controls.
A and B demonstrates increased microglial activation and reduced glucose metabolism
respectively in a PDD. C and D demonstrates increased microglial activation and reduction
in glucose metabolism in PD subject.
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Figure 5.
Pixel-by-pixel correlation between microglial activation, glucose metabolism, and MMSE
scores in PDD subjects.
A demonstrates the significant clusters using regression analysis of [11C]PK11195 BP
against MMSE score in 11 PDD subjects at a cluster threshold of p<0.00005 with extent
threshold of 200 voxels. Cortical microglial activation was correlated with MMSE in PDD
subjects
B demonstrates the significant clusters using regression analysis of rCMRGlc against
MMSE score in 11 PDD subjects at a cluster threshold of p<0.00005 with extent threshold
of 200 voxels. Cortical rCMRGlc was correlated with the MMSE scores.
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Figure 6.
Semi-quantitative figure showing microglial activation vs hypometabolism overlaid on SPM
templates. A demonstrates [11C](R)PK11195 BP map overlaid on rCMRGlc map in PDD,
while B demonstrates the same in a PD subject. Microglial activation is represented in red,
rCMRglc in blue, while purple demonstrates the overlap.
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